UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Monitoring illicit psychostimulants and related health issues
Brunt, T.M.
Publication date
2012
Link to publication
Citation for published version (APA):
Brunt, T. M. (2012). Monitoring illicit psychostimulants and related health issues. Boxpress.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
175
References
Aerts LA, Mallaret M, Rigter H (2000) N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. Addict. Biol. 5, 269-282
Allott R, Paxton R, Leonard R. (1999). Drug education: a review of British Government policy and evidence on effectiveness. Health Educ. Res. 14, 491-505
Ames B.N., Magaw R., Gold L.S. Ranking possible carcinogenic hazards.
Science 1987; 236: 271-280.
van Amsterdam JG, Best W, Opperhuizen A, de Wolff FA. (2004). Evaluation of a procedure to assess the adverse effects of illicit drugs. Regul. Toxicol. Pharmacol. 39(1), 1-4
van Amsterdam, J., Opperhuizen, A., Koeter, M., & van den Brink, W. (2010). Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. European Addiction Research 16(4), 202-207.
Ansah T.A., Wade L.H., Shockley D.C. (1993). Effects of calcium channel entry blockers on cocaine and amphetamine-induced motor activities and toxicities. Life Sci. 53, 1947-1956
Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. (2009) Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci. Int. 186, 63-67
Apostolakos M.J., Varon M.E. (1996). Antiarrhythmic and anti-ischemic properties of calcium-channel antagonists. New Horiz. 4, 45-57. Asbridge, M., & Weerasinghe, S. (2009). Homicide in Chicago from 1890 to
1930: prohibition and its impact on alcohol- and non-alcohol-related homicides. Addiction 104(3), 355-364.
Asia and Pacific Amphetamine-Type Stimulants Information Centre (APAIC). (2010). http://www.apaic.org/
Baumann MH, Wang X, Rothman RB. (2007). 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology (Berl) 189(4), 407-424
176
Baumgarten HG, Lachenmayer L. (2004). Serotonin neurotoxins-past and present. Neurotox. Res. 6(7-8), 589-614
Baylen, CA, Rosenberg, H (2006) A review of the acute subjective effects of MDMA/ecstasy. Addiction 101, 933-947.
BBC news (2009) Police warning over 'bubble' drug. Available at: http://news.bbc.co.uk/2/hi/uk_news/england/tees/8370130.stm. Becker J, Neis P, Röhrich J, Zörntlein S (2003) A fatal
paramethoxymethamphetamine intoxication. Leg Med (Tokyo) 5, S138-141
Belhadj-Tahar, H, Sadeg, N. (2005). Methcathinone: a new postindustrial drug. Forensic Sci. Int. 153, 99-101.
Behrman, A.D. (2008). Luck of the draw: common adulterants found in illicit drugs. J Emerg Nurs 34, 80-82.
Benschop, A., Rabes, M., & Korf, D.J. (2002). Pill Testing, Ecstasy &
Prevention. Rozenberg, Amsterdam, The Netherlands.
Bertol, E., Trignano, C., Di Milia, M.G., Di, P.M., Mari, F. (2008). Cocaine-related deaths: an enigma still under investigation. Forensic Sci. Int. 176, 121-123.
Blanken P, Hendriks VM, van Ree JM, van den Brink W. (2010). Outcome of long-term heroin-assisted treatment offered to chronic, treatment-resistant heroin addicts in the Netherlands. Addiction 105(2), 300-308
Boer, de, D, Bosman IJ, Hidvégi E, Manzoni C, Benkö AA, dos Reys LJ, Maes RA. (2001). Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci. Int. 121, 47-56
ter Bogt, T. (1997). One two three four... popmuziek, jeugdcultuur en stijl. Boom Juridisch, Amsterdam
Bossong, M., Brunt, T.M., Van Dijk, J.P., Rigter, S., Hoek, J., Goldschmidt ,H., & Niesink, R.J. (2010). mCPP: an undesired addition to the ecstasy market. Journal of Psychopharmacology 24(9), 1395-1401 Bossong MG, Van Dijk JP, Niesink RJ. (2005). Methylone and mCPP, two
177
Boyer EW, Quang L, Woolf A, Shannon M, Magnani B. (2001). Dextromethorphan and ecstasy pills. JAMA 285, 409-410
Braida D, Zani A, Capurro V, Rossoni G, Pegorini S, Gori E, Sala M. (2008). Diazepam protects against the enhanced toxicity of cocaine adulterated with atropine. J. Pharmacol. Sci. 107, 408-418
Brandt SD, Sumnall HR, Measham F, Cole J. (2010a). Second generation mephedrone. The confusing case of NRG-1. BMJ. 341, c3564
Brandt SD, Sumnall HR, Measham F, Cole J. (2010b). Analyses of second-generation „legal-highs‟ in the UK: Initial findings. Drug Test. Anal. 2(8), 377-382
Brittebo E.B. (1987).Metabolic activation of phenacetin in rat nasal mucosa: dose-dependent binding to the glands of Bowman. Cancer
Res. 47, 1449-1456
Brownstein, H.H., Taylor, B.G. (2007). Measuring the stability of illicit drug markets: why does it matter? Drug Alcohol Dependence. 90 Suppl 1, S52-S60.
Brunt, T.M., Rigter, S., Hoek, J., Vogels, N., van, D.P., Niesink, R.J. (2009). An analysis of cocaine powder in the Netherlands: content and health hazards due to adulterants. Addiction 104, 798-805. Brunt TM, Poortman A, Niesink RJ, van den Brink W. (2011). Instability of
the ecstasy market and a new kid on the block: mephedrone. J.
Psychopharmacology 25(11), 1543-1547
Brunt TM, van Laar M, Niesink RJM, van den Brink W. (2010). The relationship of quality and price of the psychostimulants cocaine and amphetamine with health care outcomes. Drug Alcohol Dependence 111(1-2), 21-29
Buisman W. et al. (Eds.). (2000). Handboek Verslaving: hulpverlening,
preventie en beleid. (Vol. C-3130, pp.1-24). Houten, Bohn Stafleu &
Van Loghum
Butler GK, Montgomery AM. (2004). Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use. Drug Alcohol Dependence. 76(1), 55-62
Butler RA, Sheridan JL (2007) Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills
178
(BZP-party pills) amongst young people in New Zealand. Harm
Reduct. J. 4, 18
Buttner A., Mall G., Penning R., Sachs H., Weis S. (2003). The neuropathology of cocaine abuse. Leg Med (Tokyo) 5 Suppl 1, S240-S242.
Bytzer P, Hallas J. (2000). Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions.
Aliment. Pharmacol. Ther. 14, 1479-1484
Caldicott DG, Edwards NA, Kruys A, Kirkbride KP, Sims DN, Byard RW, Prior M, Irvine RJ. (2003). Dancing with "death": p-methoxyamphetamine overdose and its acute management. J.
Toxicol. Clin. Toxicol. 41, 143-154
Calkins, RF, Aktan, GB, Hussain, KL (1995) Methcathinone: the next illicit stimulant epidemic? J. Psychoactive Drugs 27, 277-285
Callaghan PD, Irvine RJ, Daws LC. (2005). Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after
acute para-methoxyamphetamine and
3,4-methylenedioxymethamphetamine revealed by chronoamperometry. Neurochem. Int. 47, 350-361
Callaghan, R.C., Cunningham, J.K., Victor, J.C., & Liu, L.M. (2009). Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions. Drug and Alcohol Dependence, 105(3), 185-193 Camilleri AM, Caldicott D (2005) Underground pill testing, down under.
Forensic Sci. Int. 151, 53-58
Carhart-Harris RL, King LA, Nutt DJ. (2011). A web-based survey on mephedrone. Drug Alcohol Dependence
doi:10.1016/j.drugalcdep.2011.02.011
Caulkins, J.P., & Reuter, P. (1997). Setting goals for drug policy: harm reduction or use reduction? Addiction 92(9), 1143-1150
Caulkins, J.P. (2001). Drug prices and emergency department mentions for cocaine and heroin. Am. J. Public Health 91, 1446-1448
Caulkins, J.P. (2007). Price and purity analysis for illicit drug: data and conceptual issues. Drug Alcohol Dependence 90 Suppl 1, S61-S68
179
Chiaia AC, Banta-Green C, Field J. (2008). Eliminating solid phase extraction with large-volume injection LC/MS/MS: analysis of illicit and legal drugs and human urine indicators in U.S. wastewaters.
Environ. Sci. Technol. 42(23), 8841-8848
Cohen BM, Butler R. (2010). BZP-party pills: a review of research on benzylpiperazine as a recreational drug. Int. J. Drug Policy 22, 95-101
Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA. (2002). The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 97, 1531-1536
Cole, J.C., Goudie, A.J., Field, M., Loverseed, A.C., Charlton, S., & Sumnall, H.R. (2008). The effects of perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug and Alcohol Dependence 94(1-3), 183-190
Compas, B., Hinden, B.R. & Gerhardt, C.A. (1995). Adolescent development: Pathways of risk and resilience. Ann. Rev. Psychology 46, 265–293
Costa Storti C., De Grauwe P. (2009). Globalization and the price decline of illicit drugs. Int. J. Drug Policy 20, 48-61
Cozzi, NV, Foley, KF. (2003). Methcathinone is a substrate for the serotonin uptake transporter. Pharmacol. Toxicol. 93, 219-225. Cuijpers P, Jonkers R, de Ja W. (2002). The effects of drug abuse
prevention at school: the 'Healthy School and Drugs' project.
Addiction 97(1), 67-73.
Cunningham, J.K., & Liu, L.M. (2003). Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 98(9), 1229-1237
Cunningham ,J.K., & Liu, L.M. (2005). Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction 100(4), 479-488
Cunningham, J.K., Liu, L.M., & Muramoto, M. (2008). Methamphetamine suppression and route of administration: precursor regulation impacts
180
on snorting, smoking, swallowing and injecting. Addiction 103(7), 1174-1186
Cunningham RS. (1997). 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Oncol. Nurs. Forum 24, 33-40 Dal Cason, TA, Young, R, Glennon, RA. (1997). Cathinone: an
investigation of several N-alkyl and methylenedioxy-substituted analogs. Pharmacol. Biochem. Behav. 58: 1109-1116
Dams R, De Letter EA, Mortier KA, Cordonnier JA, Lambert WE, Piette MH, Van Calenbergh S, De Leenheer AP. (2003). Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study J. Anal. Toxicol. 27(5), 318-322
Dancesafe. (2010). http://www.ecstasydata.org/stats.php
Darke, S., Kaye, S., Topp, L. (2002). Cocaine use in New South Wales, Australia, 1996-2000: 5 year monitoring of trends in price, purity, availability and use from the illicit drug reporting system. Drug
Alcohol Dependence 67, 81-88
Dave, D. (2006). The effects of cocaine and heroin price on drug-related emergency department visits. J. Health Econ. 25, 311-333
Degenhardt, L., Roxburgh, A., Black, E., Bruno, R., Campbell, G., Kinner, S., Fetherston, J. (2008). The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev. 27, 243-252
Derzon J.H. & Lipsey M.W. (2002). A meta-analysis of the effectiveness of
mass-communication for changing substance-use knowledge, attitudes and behavior. Mass Media and Drug Prevention: Classic
and Contemporary Theories and Research. Matwah, Lawrence Erlbaum Associates Publishers, New Jersey, 231-258
Dick, D, Torrance, C. (2010). MixMag Drugs Survey. Mix Mag 225, 44-53 Ding X., Kaminsky L.S. (2003). Human extrahepatic cytochromes P450:
function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev.
Pharmacol. Toxicol. 43, 149-73
Docherty JR, Green AR. (2010). The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine
181
(MDMA, ecstasy) and its derivatives. Br. J. Pharmacol. 160(5), 1029-1044
Doekhie, J., Nabben, T., Korf, D. (2009). Trendwatch 2008-2009. Rozenberg Publishers, Amsterdam
Dughiero G, Schifano F, Forza G. (2001). Personality dimensions and psychopathological profiles of Ecstasy users. Hum. Psychopharmacology 16(8), 635-639
Dumont GJ, Verkes RJ. (2006). A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J. Psychopharmacology 20, 176-187
Edeleano L. (1887). Über einige derivative der Phenylmethacrylsaure und der Phenylisobuttersaure. Berl. Dtsch. Chem. Ges. 20, 616-622. Edwards, G. (2001). Time-series analysis as an important contemporary
statistical tool. Addiction 96(7), 941-942
El-Mallakh RS, Abraham HD. (2007). MDMA (Ecstasy). Ann. Clin.
Psychiatry. 19(1), 45-52
Epstein D.H., Preston K.L., Stewart J., Shaham Y. (2006). Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure. Psychopharmacology (Berl) 189, 1-16
Erowid. (2006). Erowid 4-Fluoroamphetamine (para-Fluoroamphetamine)
Vault, http://www.erowid.org/chemicals/4_fluoroamphetamine/
Erowid. (2010a). LSD. http://www.erowid.org/chemicals/ lsd/lsd_article3.shtml
Erowid. (2010b). Erowid Experience Vaults: 4-Methylmethcathinone
Reports, http://www.erowid.org/experiences/subs/
exp_4Methylmethcathinone.shtml
Europol. (2007). Amphetamine-type Stimulants in the European Union
1998-2007. Te Hague, The Netherlands,
http://www.europol.europa.eu/publications/
Serious_Crime_Overviews/EuropolUNGASSAssessment.PDF
EMCDDA (2003-2011) European information system and database on new drugs, EWS final reports 2003-2011, http://ednd.emcdda.europa.eu/ EMCDDA. (2008). Annual Report 2008. http://www.emcdda.europa.eu/
182
EMCDDA. (2007). Annual Report 2007. http://www.emcdda.europa.eu/ html.cfm/ index44682EN.html
EMCDDA. (2010). Annual Report 2010. http://www.emcdda.europa.eu/ attachements.cfm/ att_120104_EN_EMCDDA_AR2010_EN.pdf EMCDDA. (2007). Cocaine and crack cocaine: a growing public health
issue.
http://www.emcdda.europa.eu/attachements.cfm/att_44748_EN_TDS I07002ENC.pdf
EMCDDA. (2009). Annual Report 2009. http://www.emcdda.europa.eu/ attachements.cfm/ att_93236_EN_EMCDDA_AR2009_EN.pdf
EMCDDA. (2010). EMCDDA and Europol step up information collection on
mephedrone. Available at: http://www.emcdda.europa.eu/
publications/drugnet/online/2010/69/article3
EMCDDA. (2010). National reports 2005-2009.
http://www.emcdda.europa.eu/publications
EMCDDA. (2010). Statistical bulletins 2004-2009.
http://www.emcdda.europa.eu/stats/archive
EMCDDA. (2010). EWS final reports 2004 – 2009. http://ednd.emcdda.europa.eu/
Europol-EMCDDA. (2010). Annual Report on the implementation of Council Decision 2005/387/JHA,http://www.emcdda.europa.eu/
attachements.cfm/att_132857_EN_EMCDDA-Europol%20Annual%20Report%202010A.pdf
EMCDDA. (2011). Report on the risk assessment of mephedrone in the
framework of the Council Decisionon new psychoactive substances.
http://www.emcdda.europa.eu/attachements.cfm/att_116646_EN_T DAK11001ENC_WEB-OPTIMISED%20FILE.pdf
Evans-Brown M, Bellis MA, McVeigh J. (2011). Should "legal highs" be regulated as medicinal products? BMJ. 342, d1101
Falck RS, Carlson RG, Wang J, Siegal HA. (2004). Sources of information about MDMA (ecstasy): perceived accuracy, importance, and implications for prevention among young adult users. Drug Alcohol
183
Felgate HE, Felgate PD, James RA, Sims DN, Vozzo DC. (1998). Recent paramethoxyamphetamine deaths. J. Anal. Toxicol. 22(2), 169-172 Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML.
(2004). Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 37, 180-188
Fischer JF, Cho AK. (1979). Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J.
Pharmacol. Exp. Ther. 1979 208(2), 203-209
Fleckenstein AE, Gibb JW, Hanson GR. (2000). Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur. J. Pharmacol. 406(1), 1-13
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. (2007). New insights into the mechanism of action of amphetamines. Annu. Rev.
Pharmacol. Toxicol. 47, 681-698
Florin SM, Kuczenski R, Segal DS. (1994). Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment. Brain Res. 654(1), 53-62
Foltin R.W., Fischman M.W., Levin F.R. (1995). Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Dependence 37, 193-210
Frishman W.H., Del Vecchio A., Sanal S., Ismail A. (2003). Cardiovascular manifestations of substance abuse part 1: cocaine. Heart Dis. 5, 187-201
Fry E, Levi J. (2009). Pharmacology and Abuse of Cocaine,
Amphetamines, Ecstasy and Related Designer Drugs.
Springer-Verlag, New York
Fucci N., De Giovanni N. (1998). Adulterants encountered in the illicit cocaine market. Forensic Sci. Int. 95, 247-252
Fucci N. (2007). Unusual adulterants in cocaine seized on Italian clandestine market. Forensic Sci. Int. 172, e1
184
Galbis-Reig D. (2004). Sigmund Freud, MD: Forgotten Contributions to Neurology, Neuropathology, and Anesthesia. Internet Journal of
Neurology 3(1)
Gamma A, Jerome L, Liechti ME, Sumnall HR. (2005). Is ecstasy perceived to be safe? A critical survey. Drug Alcohol Dependence 77, 185-193
Gelper, S., Croux, C. (2006). Multivariate out-of-sample tests for Granger causality. Comp. Stat. Dat. Anal. 51, 3319-3329
Gijsman HJ, Cohen AF, van Gerven JM. (2004). The application of the principles of clinical drug development to pharmacological challenge tests of the serotonergic system. J. Psychopharmacology 18, 7-13
Gilmour, S., Degenhardt, L., Hall, W., & Day, C. (2006). Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Medical
Research Methodology 6, 16.
Giraudon I, Bello PY. (2007). Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004. Subst. Use
Misuse 42, 1567-1578
Glauser, J., Queen, J.R. (2007). An overview of non-cardiac cocaine toxicity. J. Emerg. Med. 32, 181-186
Glennon RA, Ismaiel AE, McCarthy BG, Peroutka SJ. (1989). Binding of arylpiperazines to 5-HT3 serotonin receptors: results of a structure-affinity study. Eur. J. Pharmacol. 168, 387-392
Gold MS. (1993). Cocaine. Plenum Medical Book Co, New York
Goldschmidt HMJ. (2004). The NEXUS vision. An alternative to the reference value concept. Clin. Chem. Lab. Med. 42, 868-873
Goldstone, MS. (1993). 'Cat': methcathinone--a new drug of abuse. JAMA
269, 2508
Goudie, A.J., Sumnall, H.R., Field, M., Clayton, H., & Cole, J.C. (2007). The effects of price and perceived quality on the behavioural economics of alcohol, amphetamine, cannabis, cocaine, and ecstasy purchases. Drug and Alcohol Dependence 89(2-3), 107-115
185
Gouzoulis-Mayfrank E, Thelen B, Habermeyer E, Kunert HJ, Kovar KA, Lindenblatt H, Hermle L, Spitzer M, Sass H. (1999). Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.
Psychopharmacology (Berl) 142, 41-50
Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, Pelz S, Becker S, Kunert HJ, Fimm B, Sass H. (2000). Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J. Neurol.
Neurosurg. Psychiatry 68, 719-725
Gouzoulis-Mayfrank, E., & Daumann, J. (2006). The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J. Psychopharmacology 20(2), 188-193
Gouzoulis-Mayfrank E, Daumann J. (2006). Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 101(3), 348-361
Grov, C., Kelly, B.C., & Parsons, J.T. (2009). Polydrug use among club-going young adults recruited through time-space sampling.
Substance Use and Misuse 44(6), 848-864
Gu J., Cui H., Behr M., Zhang L., Zhang Q.Y., Yang W. et al. (2005). In vivo mechanisms of tissue-selective drug toxicity: effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol.
Pharmacol. 67, 623-30
Gyermek L. (1998). Pharmacology of Antimuscarinic Agents. Kane H, editor. Pharmacology and toxicology: basic and clinical aspect series. Hollinger, M. A, editor. Boca Raton, Florida: CRC Press p. 1-477 Gygi, MP, Gibb, JW, Hanson, GR. (1996). Methcathinone: an initial study
of its effects on monoaminergic systems. J. Pharmacol. Exp. Ther.
276, 1066-1072
Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM,
186
Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE. (2011). 4-Methylmethcathinone(mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. DOI:10.1124/ jpet.111.184119
Hartgers C, Buning EC, van Santen GW, Verster AD & Coutinho RA. (1989). The impact of the needle and syringe-exchange programme in Amsterdam on injecting risk behaviour. AIDS 3, 571-576.
Hatzidimitriou G, McCann UD, Ricaurte GA. (1999). Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J. Neurosci. 19(12), 5096-5107 Hegadoren KM, Baker GB, Bourin M. (1999). 3,4-Methylenedioxy
analogues of amphetamine: defining the risks to humans. Neurosci.
Biobehav. Rev. 23, 539-553
Helmlin H. (2010). http://www.erowid.org/psychoactives/testing/ testing_article2.shtml
Henderson, LA, Glass, WJ. (1994). LSD: Still with Us after All These
Years. Wiley & Sons, John Incorporated, San Fransisco, CA
Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E. (1993). Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents? Neuropsychopharmacology 8, 171-176
Herttua, K., Mäkelä, P., & Martikainen, P. (2008). Changes in alcohol-related mortality and its socioeconomic differences after a large reduction in alcohol prices: a natural experiment based on register data. Am. J. of Epidemiology, 168(10), 1110-1118
Higgins GA, Kilpatrick GJ. (1999). 5-HT(3) receptor antagonists. Expert.
Opin. Investig. Drugs 8, 2183-2188
Hinson J.A. (1983). Reactive metabolites of phenacetin and acetaminophen: a review. Environ. Health Perspect. 49, 71-79 Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K. (2009).
Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. J. Gastroenterol. Hepatol. 24, 537-546
187
Horowitz B.Z., Panacek E.A., Jouriles N.J. (1997). Severe rhabdomyolysis with renal failure after intranasal cocaine use. J. Emerg. Med. 15, 833-837
Hosmer DW, Lemeshow S. (2000). Applied logistic regression Second Edition. Wiley, University of Massachusetts Amherst, Massachusetts
Huerta-Fontela M. et al. (2007). Ultraperformance liquid chromatography-tandem mass spectrometry analysis of stimulatory drugs of abuse in wastewater and surface waters. Anal. Chem. 79, 3921-3829
Hummel M, Unterwald EM. (2002). D1 dopamine receptor: a putative neurochemical and behavioral link to cocaine action. J. Cell Physiol. 191(1), 17-27
Huxster, JK, Pirona, A, Morgan, MJ. (2006). The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans. J.
Psychopharmacology 20, 281-290
Hyatt, R.R., Jr., Rhodes, W. (1995). The price and purity of cocaine: the relationship to emergency room visits and death, and to drug use among arrestees. Stat. Med. 14, 655-668
Jaehne EJ, Salem A, Irvine RJ. Pharmacological and behavioral derterminants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia. Psychopharmacology (Berl) 194(1), 41-52 Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, Russell BR (2010)
Determining the subjective effects of TFMPP in human males.
Psychopharmacology Berl 211, 347-353
Jeffrey W. Colour Tests. In: Moffat A.C, Osselton M.D., Widdop B., editors. (2003). Clarke's Analysis of Drugs and Poisons, Third Edition. 3 ed. London: Pharmaceutical Press p. 279-300.
Jerrard, DA. (1990). "Designer drugs"--a current perspective. J. Emerg.
Med. 8, 733-741.
Johnston, J., Barratt, M.J., Fry, C.L., Kinner, S., Stoové, M., Degenhardt, L., George, J., Jenkinson, R., Dunn, M. & Bruno, R. (2006). A survey of regular ecstasy users‟ knowledge and practices around
188
determining pill content and purity: Implications for policy and practice. Int. J. Drug Policy 17, 464-472
Johnstone AC, Lea RA, Brennan KA, Schenk S, Kennedy MA, Fitzmaurice PS. (2007). Benzylpiperazine: a drug of abuse? J. Psychopharmacology 21, 888-894
Johansen, S. (1996). Likelihood-Based Inference in Cointegrated Vector
Autoregressive Models. 1st ed. Oxford University Press, Oxford,
United Kingdom.
Johansen SS, Hansen AC, Müller IB, Lundemose JB, Franzmann MB. (2003). Three fatal cases of PMA and PMMA poisoning in Denmark.
J. Anal. Toxicol. 27, 253-256
Jones S, Kauer JA. (1999). Amphetamine depresses excitatory synaptic transmission via serotonin receptors in the ventral tegmental area. J.
Neurosci. 19(22), 9780-9787
Kalasinsky KS, Hugel J, Kish SJ. (2004). Use of MDA (the "love drug") and methamphetamine in Toronto by unsuspecting users of ecstasy (MDMA). J. Forensic Sci. 49, 1106-1112
Kasprzyk-Hordern, B. Dinsdale, R.M. & Guwy, A.J. (2008). Multiresidue methods for the analysis of pharmaceuticals, personal care products and illicit drugs in surface water and wastewater by solid-phase extraction and ultra performance liquid chromatography-electrospray tandem mass spectrometry. Anal. Bioanal. Chem. 391, 1293-1308 Katz N et al. (2010). Usefulness of prescription monitoring programs for
surveillance: analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006 Pharmacoepidemiol. Drug Safety 19, 115-123
Kelly JP. (2011). Cathinone derivatives: A review of their chemistry, pharmacology and toxicology. Drug Test. Anal. 3(7-8), 439-453 Keijsers L., Bossong M G, Waarlo A.J. (2007). Participatory evaluation of a
Dutch warning campaign for substance-users. Health Risk Soc. 10, 283-295.
Kenyon SL, Ramsey JD, Lee T, Johnston A, Holt DW. (2005). Analysis for identification in amnesty bin samples from dance venues. Ther.
189
Kerr T, Small W, Moore D, Wood E. (2007). A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility. Int. J. Drug Policy 18(1), 37-45
King LA. (2009). Forensic Chemistry of Substance Misuse: A Guide to
Drug Control. Royal Society of Chemistry, Cambridge, UK
Kita T, Miyazaki I, Asanuma M, Takeshima M, Wagner GC. (2009). Dopamine-induced behavioral changes and oxidative stress in methamphetamine-induced neurotoxicity. Int. Rev. Neurobiol. 88, 43-64
Knuepfer, M.M. (2003). Cardiovascular disorders associated with cocaine use: myths and truths. Pharmacol. Ther. 97, 181-222.
Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA. (2008). Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J. Clin. Psychopharmacology 28, 432-440
Konijn K, Pennings E, De Wolff F. (1997). XTC: Klinische en
Toxicologische Aspecten. LUMC, Leiden
Korf, D.J., Benschop, A., & Brunt, T.M. (2003). Pill testing in The
Netherlands. Rozenberg, Amsterdam, The Netherlands.
de Kort, M. & Cramer, T. (1999). Pragmatism versus ideology: Dutch drug policy Journal of Drug Issues 29, 473–492.
Koski, A., Sirén, R., Vuori, E., & Poikolainen, K. (2007). Alcohol tax cuts and increase in alcohol-positive sudden deaths: a time-series intervention analysis. Addiction 102(3), 362-368
Kraner JC, McCoy DJ, Evans MA, Evans LE, Sweeney BJ. (2001). Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J. Anal. Toxicol. 25, 645-648 Kriener H et al. (2001). An inventory of on-site pill-testing interventions in
the European Union. Vienna Social Projects. EMCDDA, Lisbon Laar, van, M.W., Cruts, A.A.N., Verdurmen, J.E.E., van Ooyen-Houben,
M.M.J., Meijer, R.F., (2008). The Netherlands National Drug Monitor:
190
Laar, van, M.W., Cruts, A.A.N., van Ooyen-Houben, M.M.J., Meijer, R.F., & Brunt T.M. (2010). The Netherlands National Drug Monitor: Annual
Report 2009. Trimbos Institute, Utrecht, The Netherlands.
Laar, van, M.W., Cruts, A.A.N., van Ooyen-Houben, M.M.J., Meijer, R.F., & Brunt T.M. (2011). The Netherlands National Drug Monitor: Annual
Report 2010. Trimbos Institute, Utrecht, The Netherlands.
Ladroue, C., Guo, S., Kendrick, K., Feng, J. (2009). Beyond element-wise interactions: identifying complex interactions in biological processes. PLoS One. 4, e6899
Lange, R.A., Hillis, L.D. (2001). Cardiovascular complications of cocaine use. N. Engl. J. Med. 345, 351-358
Legleye S, Ben Lakhdar C, Spilka S.(2008). Two ways of estimating the euro value of the illicit market for cannabis in France. Drug Alcohol
Rev. 27(5), 466-472
Leikin, J.B., Morris, R.W., Warren, M., Erickson, T. (2001). Trends in a decade of drug abuse presentation to an inner city ED. Am. J.
Emerg. Med. 19, 37-39.
Liechti ME, Gamma A, Vollenweider FX. (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology Berl 154, 161-168
Liechti ME, Vollenweider FX. (2001). Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacology 16(8), 589-598
Lin DL, Liu HC, Yin HL. (2007). Recent paramethoxymethamphetamine (PMMA) deaths in Taiwan. J. Anal. Toxicol. 31, 109-113
Lin JC, Bangs N, Lee H, Kydd RR, Russell BR. (2009). Determining the subjective and physiological effects of BZP on human females.
Psychopharmacology Berl 207, 439-446
Lin JC, Jan RK, Lee H, Jensen MA, Kydd RR, Russell BR. (2011). Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology Berl 214, 761-768
191
Lora-Tamayo C, Tena T, Rodríguez A, Moreno D, Sancho JR, Enseñat P, Muela F. (2004). The designer drug situation in Ibiza. Forensic Sci.
Int. 140, 195-206
Llorca P.M., Spadone C., Sol O., Danniau A., Bougerol T., Corruble E. et
al. (2002). Efficacy and safety of hydroxyzine in the treatment of
generalized anxiety disorder: a 3-month double-blind study. J Clin
Psychiatry 63, 1020-1027
Lütkepohl, H. (2006). New Introduction to Multiple Time Series Analysis, 1st ed. Springer-Verlag, New York, United States
Marona-Lewicka D, Rhee GS, Sprague JE, Nichols DE. (1995). Psychostimulant-like effects of p-fluoroamphetamine in the rat. Eur.
J. Pharmacol. 287, 105-113
Matok I, Gorodischer R, Koren G, Sheiner E, Wiznitzer A, Levy A. (2009). The safety of metoclopramide use in the first trimester of pregnancy.
N. Engl. J. Med. 360, 2528-2535
Matthews A, Bruno R, Johnston J, Black E, Degenhardt L, Dunn M. (2009). Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users. Drug
Alcohol Dependence 100(1-2), 24-31
Maurer HH, Kraemer T, Springer D, Staack RF. (2004). Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther. Drug Monit. 26, 127-131
McCance-Katz, E.F., Kosten, T.R., Jatlow, P. (1998). Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone--a multiple-dose study. Biol. Psychiatry 44, 250-259
McCann UD, Ridenour A, Shaham Y, Ricaurte GA. (1994). Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.
Neuropsychopharmacology 10(2), 129-138
McCann, UD, Wong, DF, Yokoi, F, Villemagne, V, Dannals, RF, Ricaurte, GA. (1998). Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence
192
from positron emission tomography studies with [11C]WIN-35,428. J.
Neurosci. 18, 8417-22.
McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. (1998). Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 352(9138), 1433-1437
McCann UD, Eligulashvili V, Ricaurte GA. (2000). (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42(1), 11-16 McCann, U.D., Ricaurte, G.A. (2004). Amphetamine neurotoxicity:
accomplishments and remaining challenges. Neurosci. Biobehav.
Rev. 27, 821-826
McCleary, R., & Hay, R.A. (1980). Applied Time Series Analysis for the
Social Sciences. Sage Publications, Beverly Hills, CA
McElrath K, O'Neill C. (2011). Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply.
Int. J. Drug Policy 22, 120-127
McKinney C.D., Postiglione K.F., Herold D.A. (1992). Benzocaine-adultered street cocaine in association with methemoglobinemia.
Clin. Chem. 38, 596-597
McTavish J.R. (2004). Pain and Profits: The History of the Headache and
Its Remedies in America. 2 ed. New Brunswick, NJ: Rutgers
University Press
Measham, F, Moore, K, Newcombe, R, Welch, Z. (2010). „Tweaking, Bombing, Dabbing and Stockpiling: The emergence of mephedrone and the perversity of prohibition‟. Drugs and Alcohol Today 10, 14-21.
Medina, K.L., & Shear, P.K. (2007). Anxiety, depression, and behavioral symptoms of executive dysfunction in ecstasy users: contributions of polydrug use. Drug and Alcohol Dependence 87, 303-311
Mensink, C. & Spruit, I.P. (1999). Jaarboek Verslaving 1998. Bohn Stafleu Van Loghum, Houten/Diegem.
193
Miksys S., Tyndale R.F. (2004). The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab.
Rev. 36, 313-33
Milhazes, N., Martins, P., Uriarte, E., Garrido, J., Calheiros, R., Marques, M.P., & Borges, F. (2007). Electrochemical and spectroscopic characterisation of amphetamine-like drugs: application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors. Analytica Chimica Acta 596(2), 231-241
Milliet, Q., Weyermann, C., & Esseiva, P. (2009). The profiling of MDMA tablets: a study of the combination of physical characteristics and organic impurities as sources of information. Forensic Sci. Int. 187(1-3), 58-65
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. (2011). The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J. Psychopharmacology 25(4), 439-452
Morefield KM, Keane M, Felgate P, White JM, Irvine RJ. (2011). Pill content, dose and resulting plasma concentrations of 3,4-methylendioxymethamphetamine (MDMA) in recreational 'ecstasy' users Addiction 106, 1293-1300
Morgan CJA, Muetzelfeldt L, Muetzelfeldt M, Nutt DJ, Curran HV. (2010). Harms associated with psychoactive substances: findings of the UK National Drug Survey. J. Psychopharmacology 24(2), 147-153
Morris K. (2010). UK places generic ban on mephedrone drug family.
Lancet 375, 1333-1334
Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS. (2011). Mephedrone (4-Methylmethcathinone, “Meow”): Acute Behavioural Effects and Distribution of Fos Expression in Adolescent Rats. Add.
Biol. In press
Mounteney J, Haugland S. (2009). Earlier warning: a multi-indicator approach to monitoring of trends in the illicit use of medicines. Int. J.
194
Murphy PN, Wareing M, Fisk J (2006) Users' perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study. J.
Psychopharmacology 20, 447-455
Nabben, T. (2010). High Amsterdam. Ritme, roes en regels in het uitgaansleven. Candide, Amsterdam
Nagai F, Nonaka R, Satoh Hisashi Kamimura K. (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur. J. Pharmacol. 559, 132-137 Newcombe, R (2009) The use of Mephedrone (MCAT, Meow) in
Middlesbrough. Lifeline Publications and Research: Manchester. Available at: http://www.lifeline.org.uk/docs/M-cat%20report% 20small.pdf
Nichols DE. (1986). Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J. Psychoactive Drugs 18(4), 305-313
Nichols D. (2011). Legal highs: the dark side of medicinal chemistry.
Nature 469(7328), 7
Niemann A. (1860). Ueber eine neue organische Base in den Cocablättern.
Archiv der Pharmazie 153 (2), 129–256
Nolte K.B. (1991). Rhabdomyolysis associated with cocaine abuse. Hum.
Pathol. 22, 1141-1145
Nutt, D., King, L.A., Saulsbury, W., Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse.
Lancet 369(9566), 1047-1053
Nutt, D.J., King, L.A., & Phillips, L.D; Independent Scientific Committee on Drugs. (2010). Drug harms in the UK: a multicriteria decision analysis. Lancet 376(9752), 1558-1565
Nuijs van, et al. (2009). Cocaine and metabolites in waste and surface water across Belgium. Environ. Pol. 157(1), 123-129
Pai, S.A., Lakshmi, P.K., Rao, B.C., Sahni, P. (2003). Pharmaceutical companies and the third world. Lancet 361, 1136-1137.
Páleníček T, Balíková M, Rohanová M, Novák T, Horáček J, Fujáková M, Höschl C. (2011). Behavioral, hyperthermic and pharmacokinetic
195
profile of para-methoxymethamphetamine (PMMA) in rats.
Pharmacol. Biochem. Behav. 98, 130-139
de Paoli G, Brandt SD, Pounder DJ. (2011). Mephedrone. Banned but still available on the internet. BMJ. 342, d1629
Parker H.J., Aldridge J., Measham F. (1998). Illegal leisure: the
normalization of adolescent recreational drug use. Routledge,
London
Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. (2002). Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum. Psychopharmacology 17, 309-312
Parrott AC. (2004a). MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50(4), 329-335
Parrott AC. (2004b). Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology Berl 173:234-241
Parrott AC. (2006). MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J. Psychopharmacology 20, 147-163
Parrott AC, Rodgers J, Buchanan T, Ling J, Heffernan T, Scholey AB. (2006). Dancing hot on Ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems reported by recreational MDMA users.
Hum. Psychopharmacology 21, 285-298
Parrott, A.C., Milani, R., Parmar, R., & Turner, J.J.D. (2001). Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems.
Psychopharmacology Berl 159(1), 77–82.
Pennings, E.J., Leccese, A.P., Wolff, F.A. (2002). Effects of concurrent use of alcohol and cocaine. Addiction 97, 773-783
196
Peroutka SJ, Newman H, Harris H. (1988). Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users.
Neuropsychopharmacology 1, 273-277
Peters J.M., Morishima H., Ward J.M., Coakley C.J., Kimura S., Gonzalez F.J. (1999). Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. Toxicol. Sci. 50, 82-9
Peterson, B.S., Potenza, M.N., Wang, Z., Zhu, H., Martin, A., Marsh, R., Plessen, K.J., Yu, S. (2009) An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am. J. Psychiatry 166, 1286-1294 Pozner C.N., Levine M., Zane R. (2005). The cardiovascular effects of
cocaine. J. Emerg. Med. 29, 173-178
Punukollu G., Gowda R.M., Khan I.A., Dogan O.M. (2003). Delayed presentation of calcium channel antagonist overdose. Am. J. Ther. 10, 132-134
Pijlman, FT, Krul, J, Niesink, RJ. (2003). Uitgaan en veiligheid. Trimbos-instituut, Utrecht
Pijlman, F.T.A., Rigter, S., Hoek J., & Niesink, R. (2005). Increased levels of total THC in cannabis sold in Dutch coffee shops. Addict. Biol. 10(2), 171-180
Ramsey, J.D., Butcher, M.A., Murphy, M.F., Lee, T., Johnston, A., Holt, D.W. (2001). A new method to monitor drugs at dance venues. BMJ. 323, 603
Rasmussen N. (2009). On Speed: The Many Lives of Amphetamine. NYU Press, New York
Refstad S. (2003). Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects. Acta Anaesthesiol. Scand. 47(10), 1298-1299
Rendic S. (2002). Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34, 83-448.
Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W. (2001). Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358(9296):1864-1869
197
Reynolds S. (1999). Generation Ecstasy : Into the World of Techno and
Rave Culture. Routledge, New York
Ricaurte GA, McCann UD, Szabo Z, Scheffel U. (2000). Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). Toxicol. Lett. 112-113, 143-146
Riedlinger TJ, Riedlinger JE. (1994). Psychedelic and entactogenic drugs in the treatment of depression. J Psychoactive Drugs 26(1), 41-55 Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. (1987). Cocaine receptors on
dopamine transporters are related to self-administration of cocaine.
Science 237(4819),1219-1223
Rodenburg G, Spijkerman R, van den Eijnden R, van de Mheen D.
National prevalence research substance abuse 2005. (2007). IVO,
Rotterdam. Available at:
http://www.hetccv.nl/binaries/ccv/dossiers/bestuurlijkhandhaven/drug sbeleid/cannabis/nationaal_onderzoek_middelengebruik.pdf
Rohanova M, Balikova M. (2009). Studies on distribution and metabolism of para-methoxymethamphetamine (PMMA) in rats after subcutaneous administration. Toxicology 259, 61-68
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS. (2001). Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41
Rothman, RB, Blough, BE, Baumann, MH. (2008). Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions In: Drug Addiction. Papaka RS,
Sadée W (eds). Springer: New York. pp 311-326.
Rowbotham M.C., Hooker W.D., Mendelson J., Jones R.T. (1987). Cocaine-calcium channel antagonist interactions.
Psychopharmacology (Berl) 93, 152-154.
Roxburgh, A., Degenhardt, L., & Breen, C. (2004). Changes in patterns of drug use among injecting drug users following changes in the availability of heroin in New South Wales, Australia. Drug and
198
Rudnick G, Wall SC. (1992). The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad.
Sci. U S A. 89(5), 1817-1821
Saunders N, Shulgin A. (1993). E for Ecstasy. 14 Neal's Yard, London Segen J. (2002). Dictionary of Modern Medicine 2nd ed. McGraw-Hill, New
York
Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH. (2003a). Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002 Hum. Psychopharmacology 18(7), 519-524
Schifano, F, Leoni, M, Martinotti, G, Rawaf, S, Rovetto, F. (2003b). Importance of cyberspace for the assessment of the drug abuse market: preliminary results from the Psychonaut 2002 project. Cyberpsychol. Behav. 6, 405-410
Schifano F, Deluca P, Baldacchino A, Peltoniemi T, Scherbaum N, Torrens M, et al. (2006a). The Psychonaut 2002 EU project. Prog. Neuropsychopharmacology Biol. Psychiatry 30, 640–646
Schifano F, Corkery J, Deluca P, Oyefeso A, Ghodse AH. (2006b). Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003).
J. Psychopharmacology 20, 456-463
Schifano, F., Corkery, J. (2008). Cocaine/crack cocaine consumption, addiction treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990 - 2004). J.
Psychopharmacol. 22, 71-79
Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, Davey Z, Corkery J, Siemann H, Scherbaum N, Farré M, Torrens M, Demetrovics Z, Ghodse AH; Psychonaut Web Mapping; ReDNet Research Groups. (2011). Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.
Psychopharmacology Berl 214, 593-602
Schindler C.W., Tella S.R., Erzouki H.K., Goldberg S.R. (1995). Pharmacological mechanisms in cocaine's cardiovascular effects.
199
Shadish, W.R., Cook, T.D., & Campbell, D.T. (2002). Experimental and
Quasi-Experimental Designs for Generalized Causal Inference.
Houghton Mifflin, Boston, MA
Shao B, Chen D, Zhang J, Wu NY and Sun CJ. (2009). Determination of 76 pharmaceutical drugs by liquid chromatography-tandem mass spectrometry in slaughterhouse wastewater. J. Chromatogr. A. 1216(47), 8312-8318
Sharkey J., Ritz M.C., Schenden J.A., Hanson R.C., Kuhar M.J. (1988). Cocaine inhibits muscarinic cholinergic receptors in heart and brain.
J. Pharmacol. Exp. Ther. 246, 1048-1052
Sharma S.P., Purkait B.C., Lahiri S.C. (2005). Qualitative and quantitative analysis of seized street drug samples and identification of source.
Forensic Sci. Int. 152(2-3), 235-240
Shearer, J., Gowing, L.R. (2004). Pharmacotherapies for problematic psychostimulant use: a review of current research. Drug Alcohol Rev. 23, 203-211
Sikk, K, Taba, P, Haldre, S, Bergquist, J, Nyholm, D, Zjablov, G, et al. (2007). Irreversible motor impairment in young addicts-ephedrone, manganism or both? Acta Neurol Scand 115: 385-389.
Simonsen KW, Kaa E, Nielsen E, Rollmann D. (2003). Narcotics at street level in Denmark. A prospective investigation from 1995 to 2000.
Forensic Sci. Int. 131, 162-170
Smithson, M., McFadden, M., & Mwesigye, S.E. (2005). Impact of Federal drug law enforcement on the supply of heroin in Australia. Addiction 100(8), 1110-1120.
Smithson, M., McFadden, M., Mwesigye, S.E., Casey, T. (2004). The impact of illicit drug supply reduction on health and social outcomes: the heroin shortage in the Australian Capital Territory. Addiction 99, 340-348.
Sparago, M, Wlos, J, Yuan, J, Hatzidimitriou, G, Tolliver, J, Dal Cason, TA,
et al. (1996). Neurotoxic and pharmacologic studies on enantiomers
of the N-methylated analog of cathinone (methcathinone): a new drug of abuse. J. Pharmacol. Exp. Ther. 279, 1043-1052.
200
Spruit, I.P. (1999). Ecstasy use and policy responses in the Netherlands.
Journal of Drug Issues 29, 653-678.
Spruit, I.P. (2001). Monitoring synthetic drug markets, trends, and public health. Substance Use and Misuse 36(1-2), 23–47
Staack RF, Maurer HH. (2003). Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J.
Anal. Toxicol. 27, 560-568
Staack R.F., Paul L.D., Schmid D., Roider G., Rolf B. (2007). Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions? J Chromatogr B Analyt
Technol Biomed Life Sci 855, 127-33.
Staack RF. (2007). Piperazine designer drugs of abuse. Lancet 369, 1411-1413
Stepens, A, Logina, I, Liguts, V, Aldins, P, Eksteina, I, Platkājis, A, et al. (2008). A Parkinsonian syndrome in methcathinone users and the role of manganese. N. Engl. J. Med. 358, 1009-17.
Sulzer D, Sonders MS, Poulsen NW, Galli A. (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Prog.
Neurobiol. 75(6), 406-433
Sumnall, H. R., Tyler, E., Wagstaff, G. F., & Cole, J.C.A. (2004). Behavioural economic analysis of alcohol, amphetamine, cocaine and ecstasy purchases by polysubstance misusers. Drug and
Alcohol Dependence 76(1), 93-99.
Sumnall HR, Cole JC, Jerome L. (2006). The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.
J. Psychopharmacology 20, 670-682
Sweetman S.C., editor. Martindale: The Complete Drug Reference. 35 ed. London: Pharmaceutical Press; 2006.
Tancer ME, Johanson CE. (2001). The subjective effects of MDMA and mCPP in moderate MDMA users. Drug. Alcohol Dependence 65, 97-101
201
Tancer M, Johanson CE. (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Dependence 72, 33-44
Tanner-Smith EE. (2006). Pharmacological content of tablets sold as "ecstasy": results from an online testing service. Drug Alcohol
Dependence 83, 247-254
Taylor, W. (2000). A Pattern Test for Distinguishing Between
Autoregressive and Mean-Shift Data. Available at:
http://www.variation.com/cpa/tech/pattern.html
Teng SF, Wu SC, Liu C, Li JH, Chien CS. (2006). Characteristics and trends of 3,4-methylenedioxymethamphetamine (MDMA) tablets found in Taiwan from 2002 to February 2005. Forensic Sci. Int. 161(2-3), 202-208
Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A. (2003). Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology Berl 167, 85-96
Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS. (2007). A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). Neuroscience 146(2), 509-514
Topp, L., Day, C., & Degenhardt, L. (2003). Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug and Alcohol Dependence 70(3), 275-286. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M,
Segura J, Camí J. (2004). Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26(2), 137-144
Toumbourou JW, Stockwell T, Neighbors C, Marlatt GA, Sturge J, Rehm J. (2007). Interventions to reduce harm associated with adolescent substance use. Lancet 369, 1391-1401
Uhl GR, Hall FS, Sora I. (2002). Cocaine, reward, movement and monoamine transporters. Mol. Psychiatry 7(1), 21-6
202
United Nations Office on Drugs and Crime (UNODC). (2011). World Drug
Report
2011.http://www.unodc.org/documents/data-and-analysis/WDR2011/World_Drug_Report_2011_ebook.pdf
UNODC. (2008). Amphetamines and Ecstasy.http://www.unodc.org/ documents/scientific/ATS/Global-ATS-Assessment-2008-Web.pdf UNODC. (2010). United Nations Office on Drugs and Crime, World Drug
Report 2010, http://www.unodc.org/documents/wdr/WDR_2010/ World_Drug_Report_2010_lo-res.pdf
United Nations Office on Drugs and Crime (UNODC). (2008). World Drug Report 2008. Vienna, United Nations. Available at: http://www.unodc.org/documents/wdr/WDR_2008/WDR_2008_eng_ web.pdf
United Nations Office on Drugs and Crime. (2007). World Drug Report
2007. Available at http://www.unodc.org/pdf/research/wdr07/
WDR_2007.pdf
United States Drug Enforcement Administration. (2010). Cocaine. http://www.justice.gov/ndic/pubs31/31379/cocaine.htm#Figure3 United States Drug Enforcement Administration. (2010). Microgram
Bulletins.
http://www.justice.gov/dea/programs/forensicsci/microgram/bulletins_ index.html
Varlibas, F, Delipoyraz, I, Yuksel, G, Filiz, G, Tireli, H, Gecim, NO. (2009). Neurotoxicity following chronic intravenous use of “Russian cocktail”.
Clin Toxicol 47, 157-60
Verheyden SL, Hadfield J, Calin T, Curran HV. (2002). Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences. Psychopharmacology Berl 161, 23-31
Vitale, S., van de Mheen, D. (2006). Illicit drug use and injuries: A review of emergency room studies. Drug Alcohol Dependence 82, 1-9.
Vogels, N., Brunt, T.M., Rigter, S., Van Dijk, P., Vervaeke, H., Niesink, R.J.M. (2009). Content of ecstasy in the Netherlands: 1993-2008.
203
Weatherburn, D., Jones, C., Freeman, K., & Makkai, T. (2003). Supply control and harm reduction: lessons from the Australian heroin 'drought'. Addiction 98(1), 83-91.
Weatherburn, D. (2009). Dilemmas in harm minimization. Addiction 104(3), 335-339.
Weber, J.E., Chudnofsky, C.R., Boczar, M., Boyer, E.W., Wilkerson, M.D., Hollander, J.E. (2000). Cocaine-associated chest pain: how common is myocardial infarction? Acad Emerg. Med. 7, 873-877.
Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, Woolverton WL. (2005). Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J.
Pharmacol. Exp. Ther. 313, 848-854
Weiner A.L., Bayer M.J., McKay C.A., Jr., DeMeo M., Starr E. (1998). Anticholinergic poisoning with adulterated intranasal cocaine. Am .J.
Emerg. Med. 16, 517-20.
Westover, A.N., McBride, S., Haley, R.W. (2007). Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch. Gen. Psychiatry 64, 495-502.
Williams, J., Pacula, R.L., Chaloupka, F.J., Wechsler, H. (2006). College students' use of cocaine. Subst. Use Misuse 41, 489-509.
de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W. (2008). Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131(Pt 11), 2936-2945
Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. (2011). Mephedrone, new kid for the chop? Addiction 106, 154-161 Wodak, A (2008) What caused the recent reduction in heroin supply in
Australia? Int. J. Drug Policy 19, 279-286.
Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison KJ. (2006). Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J.
204
Wood, E., Stoltz, J., Li, K., Montaner, J. & Kerr, T. (2006). Changes in Canadian heroin supply coinciding with the Australian heroin shortage. Addiction, 101(5), 689-695.
Wu, L.T., Parrott, A.C., Ringwalt, C.L., Yang, C., & Blazer, D.G. (2009). The variety of ecstasy/MDMA users: results from the National Epidemiologic Survey on alcohol and related conditions. The
American Journal on Addictions 18(6), 452-461.
Zuccato, E., Chiabrando, C., Castiglioni, S., Bagnati, R., Fanelli, R. (2008). Estimating community drug abuse by wastewater analysis. Environ.
